| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-23T02:12:17Z |
Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
|
Tsai M.-C.; Wang C.-C.; Lee W.-C.; Lin C.-C.; Chang K.-C.; CHIEN-HUNG CHEN; Hung C.-H.; Lin M.-T.; Hsiao C.-C.; Chen C.-L.; Chien R.-N.; Hu T.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:33Z |
Diffuse intraperitoneal metastasis after spontaneous rupture of hepatocellular carcinoma
|
Lin C.-C.; CHIEN-HUNG CHEN; Tsang Y.-M.; Jan I.-S.; Sheu J.-C. |
| 臺大學術典藏 |
2022-02-22T05:34:27Z |
Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis
|
Lin C.-C.; Liang H.-P.; Lee H.-S.; Huang G.-T.; Yang P.-M.; Ho M.-C.; Lee P.-H.; Tsang Y.-M.; Chen D.-S.; Sheu J.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:07Z |
Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
|
Tsai M.-C.; Wang C.-C.; Lee W.-C.; Lin C.-C.; Chang K.-C.; CHIEN-HUNG CHEN; Hung C.-H.; Lin M.-T.; Hsiao C.-C.; Chen C.-L.; Chien R.-N.; Hu T.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:39Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
JIH-HSIANG LEE; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; Ho C.-C.; Laio W.-Y.; Yang P.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:38Z |
Safety of gefitinib in non-small cell lung cancer treatment
|
Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:38Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Liao B.-C.; JIH-HSIANG LEE; Lin C.-C.; Chen Y.-F.; Chang C.-H.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:37Z |
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
|
Liao B.-C.; Lin C.-C.; JIH-HSIANG LEE; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:37Z |
Profile of the therascreen? EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer
|
Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:36Z |
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
|
Liao B.-C.; Lin C.-C.; JIH-HSIANG LEE; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; JIH-HSIANG LEE; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:35Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:34Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non�VSmall-cell Lung Cancer Patients
|
Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Liao W.-Y.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:34Z |
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
|
Liao B.-C.; Bai Y.-Y.; JIH-HSIANG LEE; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
JIH-HSIANG LEE; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2022-02-21T03:52:32Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; JIH-HSIANG LEE; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-21T03:52:30Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Lin C.-C.; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 臺大學術典藏 |
2022-02-21T02:04:36Z |
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
|
Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Lin C.-C.; Chen Y.-J.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2022-02-18T06:28:51Z |
Risk of colonoscopy-related complications in a fecal immunochemical test-based population colorectal cancer screening program
|
WEN-FENG HSU; Chang C.-Y.; Chang C.-C.; Chang L.-C.; Chen C.-H.; Lin C.-C.; Lin Y.-M.; Lee C.-L.; Wu H.-Y.; Lee H.-C.; Lee Y.-C.; Su M.-Y.; Lin L.-J.; Chia S.-L.; Wu M.-S.; Chiu H.-M. |
| 臺大學術典藏 |
2022-02-15T05:45:01Z |
Cutaneous presentation of disseminated cytomegalovirus infection in a non-transplant patient with hematological malignancy: A case report
|
Yu H.-C.; Liu W.-D.; Kuo P.-H.; Lin C.-C.; UN-IN WU |
| 臺大學術典藏 |
2022-02-14T07:10:40Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-02-14T05:27:17Z |
Endoscopic ultrasound ablation in a patient with multiple metastatic pancreatic tumors from adrenocorticotropic hormone-producing thymic neuroendocrine neoplasm
|
Chang L.-K.; Chen K.-C.; Cheng M.-F.; Lin C.-C.; HSIU-PO WANG; Sung C.-T.; Chen J.-H.; Yen R.-F.; Hsu C.-L.; Shih S.-R. |
| 臺大學術典藏 |
2022-02-07T07:49:00Z |
Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; SUNG-HSIN KUO; Hong R.-L.; Huang T.-C.; Yao M. |
| 臺大學術典藏 |
2022-02-07T03:29:06Z |
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
|
Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Lin C.-C.; Chen Y.-J.; Cheng A.-L.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-02-07T03:29:04Z |
Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites
|
Guo J.-C.; Lin C.-Y.; Lin C.-C.; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022-01-25T07:24:22Z |
Risk of colonoscopy-related complications in a fecal immunochemical test-based population colorectal cancer screening program
|
Hsu W.-F.; Chang C.-Y.; Chang C.-C.; Chang L.-C.; Chen C.-H.; Lin C.-C.; Lin Y.-M.; Lee C.-L.; Wu H.-Y.; Lee H.-C.; Lee Y.-C.; Su M.-Y.; Lin L.-J.; Chia S.-L.; MING-SHIANG WU; Chiu H.-M. |
| 臺大學術典藏 |
2022-01-25T05:07:25Z |
Androgen pathway stimulates MicroRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis
|
Chen P.-J.; Yeh S.-H.; Liu W.-H.; Lin C.-C.; Huang H.-C.; CHI-LING CHEN; Chen D.-S.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-25T03:25:12Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; CHI-LING CHEN; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2022-01-24T09:31:34Z |
Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus
|
Chen H.-L.; Lee C.-N.; Chang C.-H.; Ni Y.-H.; Shyu M.-K.; Chen S.-M.; Hu J.-J.; Lin H.H.; Zhao L.-L.; Mu S.-C.; Lai M.-W.; Lee C.-L.; Lin H.-M.; Tsai M.-S.; Hsu J.-J.; Chen D.-S.; Chan K.A.; Chang M.-H.; Su Y.-N.; Shih J.-C.; Chao K.-H.; Wu J.-F.; Hsu H.-Y.; CHUN-JEN LIU; Su T.-H.; Lin C.-C.; Lin P.-Y.; Yang W.-R.; Yang C.-K.; Chang Y.-K.; Chen K.-H.; Lin Y.-H.; Chen H.-J.; Pan H.-S.; Lau B.-H.; Cheng P.-J.; Chang Y.-L.; Chiueh H.-Y.; Wang T.-H.; Lo L.-M.; Hsieh C.-L.; Cheng S.-W.; Lin L.-H.; She B.-Q.; Koh K.-J.; Hung Y.-L.; Peng F.-S.; Lin Y.-C.; Wu T.-C.; Chen C.-Y.; Chen C.-P.; Huang J.-P.; Yeung C.-Y.; Lin C.-J.; Chiu W.-T.; Wang D.-S.; Lin W.-T.; Hwang K.-S.; Huang C.-F.; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT Study) |
| 臺大學術典藏 |
2022-01-24T09:31:13Z |
Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers
|
Chang K.-C.; Chang M.-H.; Lee C.-N.; Chang C.-H.; Wu J.-F.; Ni Y.-H.; Wen W.-H.; Shyu M.-K.; Lai M.-W.; Chen S.-M.; Hu J.-J.; Lin H.H.; Hsu J.-J.; Mu S.-C.; Lin Y.-C.; CHUN-JEN LIU; Chen D.-S.; Lin L.-H.; Chen H.-L.; Hwa H.-L.; Su Y.-N.; Shih J.-C.; Chao K.-H.; Hsu H.-Y.; Chiu Y.-C.; Su T.-H.; Lin C.-C.; Lin P.-Y.; Yang W.-R.; Zhao L.-L.; Yang C.-K.; Chang Y.-K.; Chen K.-H.; Lin Y.-H.; Chen H.-J.; Pan H.-S.; Lau B.-H.; Lee C.-L.; Cheng P.-J.; Chang Y.-L.; Chiueh H.-Y.; Wang T.-H.; Lo L.-M.; Hsieh C.-L.; Cheng S.-W.; Tsai M.-S.; She B.-Q.; Koh K.-J.; Hung Y.-L.; Lin H.-M.; Peng F.-S.; Wu T.-C.; Chen C.-Y.; Chen C.-P.; Huang J.-P.; Yeung C.-Y.; Lin C.-J.; Chiu W.-T.; Wang D.-S.; Lin W.-T.; Hwang K.-S.; Huang C.-F.; The Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study) |
| 臺大學術典藏 |
2022-01-24T09:31:08Z |
Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate
|
Wen W.-H.; Chen H.-L.; Shih T.T.-F.; Wu J.-F.; Ni Y.-H.; Lee C.-N.; Zhao L.-L.; Lai M.-W.; Mu S.-C.; Tung Y.-C.; Hsu H.-Y.; Chang M.-H.; Shyu M.K.; Hwa H.L.; Su Y.N.; Shih J.C.; Chao K.H.; Chiu Y.C.; Chang K.C.; CHUN-JEN LIU; Su T.H.; Chen D.S.; Chen S.M.; Lin C.C.; Lin P.Y.; Yang W.R.; Hu J.J.; Yang C.K.; Chang Y.K.; Chen K.H.; Lin H.H.; Lin Y.H.; Chen H.J.; Pan H.S.; Lau B.H.; Lee C.L.; Cheng P.J.; Chang Y.L.; Chiueh H.Y.; Wang T.H.; Hsu J.J.; Lo L.M.; Hsieh C.L.; Cheng S.W.; Tsai M.S.; Lin L.H.; She B.Q.; Peng F.S.; Lin Y.C.; Chen C.P.; Huang J.P.; Yeung C.Y.; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study) |
| 臺大學術典藏 |
2022-01-24T09:30:55Z |
Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
|
Cheng P.-N.; Chen C.-Y.; Yu M.-L.; Lin C.-C.; Lin C.-Y.; Peng C.-Y.; Tseng K.-C.; Lo C.-C.; Tseng I.-H.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-12T07:07:35Z |
Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia
|
HSIN-AN HOU; Lin C.-C.; Chou W.-C.; Liu C.-Y.; Chen C.-Y.; Tang J.-L.; Lai Y.-J.; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Lee F.-Y.; Kuo Y.-Y.; Lee M.-C.; Liu M.-C.; Liu C.-W.; Lin L.-I.; Yao M.; Huang S.-Y.; Ko B.-S.; Hsu S.-C.; Wu S.-J.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:34Z |
SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution
|
Lin C.-C.; HSIN-AN HOU; Chou W.-C.; Kuo Y.-Y.; Wu S.-J.; Liu C.-Y.; Chen C.-Y.; Tseng M.-H.; Huang C.-F.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Huang S.-Y.; Hsu S.-C.; Ko B.-S.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:33Z |
IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients
|
Yang Y.-T.; HSIN-AN HOU; Liu C.-Y.; Lin C.-C.; Chou W.-C.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Li C.-C.; Kuo Y.-Y.; Huang S.-Y.; Ko B.-S.; Chen C.-Y.; Hsu S.-C.; Lin C.-T.; Wu S.-J.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:33Z |
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution
|
Lin C.-C.; HSIN-AN HOU; Chou W.-C.; Kuo Y.-Y.; Liu C.-Y.; Chen C.-Y.; Lai Y.-J.; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Huang S.-Y.; Ko B.-S.; Wu S.-J.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:32Z |
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression
|
HSIN-AN HOU; Kuo Y.-Y.; Tang J.-L.; Chou W.-C.; Yao M.; Lai Y.-J.; Lin C.-C.; Chen C.-Y.; Liu C.-Y.; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Huang S.-Y.; Ko B.-S.; Wu S.-J.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:28Z |
GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution
|
HSIN-AN HOU; Lin Y.-C.; Kuo Y.-Y.; Chou W.-C.; Lin C.-C.; Liu C.-Y.; Chen C.-Y.; Lin L.-I.; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Huang S.-Y.; Ko B.-S.; Hsu S.-C.; Wu S.-J.; Tsay W.; Chen Y.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:27Z |
Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia
|
HSIN-AN HOU; Liu C.-Y.; Kuo Y.-Y.; Chou W.-C.; Tsai C.-H.; Lin C.-C.; Lin L.-I.; Tseng M.-H.; Chiang Y.-C.; Liu M.-C.; Liu C.-W.; Tang J.-L.; Yao M.; Li C.-C.; Huang S.Y.; Ko B.-S.; Hsu S.-C.; Chen C.-Y.; Lin C.-T.; Wu S.-J.; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:27Z |
Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)
|
Yao C.-Y.; HSIN-AN HOU; Lin T.-Y.; Lin C.-C.; Chou W.-C.; Tseng M.-H.; Chiang Y.-C.; Liu M.-C.; Liu C.-W.; Kuo Y.-Y.; Wu S.-J.; Liao X.-W.; Lin C.-T.; Ko B.-S.; Chen C.-Y.; Hsu S.-C.; Li C.-C.; Huang S.-Y.; Yao M.; Tang J.-L.; Tsay W.; Liu C.-Y.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:25Z |
Genetic alterations and their clinical implications in older patients with acute myeloid leukemia
|
Tsai C.-H.; HSIN-AN HOU; Tang J.-L.; Liu C.-Y.; Lin C.-C.; Chou W.-C.; Tseng M.-H.; Chiang Y.-C.; Kuo Y.-Y.; Liu M.-C.; Liu C.-W.; Lin L.-I.; Tsay W.; Yao M.; Li C.-C.; Huang S.-Y.; Ko B.-S.; Hsu S.-C.; Chen C.-Y.; Lin C.-T.; Wu S.-J.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:24Z |
Reduced incidence of interstitial pneumonitis after Allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation
|
Chiang Y.; Tsai C.-H.; Kuo S.-H.; Liu C.-Y.; Yao M.; Li C.-C.; Huang S.-Y.; Ko B.-S.; Lin C.-T.; HSIN-AN HOU; Chou W.-C.; Liu J.-H.; Lin C.-C.; Wu S.-J.; Hsu S.-C.; Chen Y.-C.; Lin K.-H.; Lin D.-T.; Chou H.-T.; Lu M.-Y.; Yang Y.-L.; Chang H.-H.; Liu M.-C.; Liao X.-W.; Wu J.-K.; Chou S.-C.; Cheng C.-L.; Chen C.-Y.; Tsay W.; Tien H.-F.; Tang J.-L.; Chen Y.-H. |
| 臺大學術典藏 |
2022-01-12T07:07:23Z |
Higher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in de novo acute myeloid leukemia
|
Lin C.-C.; Hsu Y.-C.; Li Y.-H.; Kuo Y.-Y.; HSIN-AN HOU; Lan K.-H.; Chen T.-C.; Tzeng Y.-S.; Kuo Y.-Y.; Kao C.-J.; Chuang P.-H.; Tseng M.-H.; Chiu Y.-C.; Chou W.-C.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:22Z |
Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia
|
HSIN-AN HOU; Lu J.-W.; Lin T.-Y.; Tsai C.-H.; Chou W.-C.; Lin C.-C.; Kuo Y.-Y.; Liu C.-Y.; Tseng M.-H.; Chiang Y.-C.; Peng Y.-L.; Tang J.-L.; Gong Z.; Lin L.-I.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:22Z |
The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model
|
Hsu Y.-C.; Chiu Y.-C.; Lin C.-C.; Kuo Y.-Y.; HSIN-AN HOU; Tzeng Y.-S.; Kao C.-J.; Chuang P.-H.; Tseng M.-H.; Hsiao T.-H.; Chou W.-C.; Tien H.-F. |
